查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1855110

口服肌腱炎药物市场报告：趋势、预测和竞争分析（至2031年）

Oral Medicine for Tenosynovitis Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球肌腱炎口服药物市场前景广阔，在医院/诊所、药局和网路购物商城等领域均蕴藏着巨大商机。预计2025年至2031年间，全球肌腱炎口服药物市场将以3.5%的复合年增长率成长。推动此市场成长的主要因素包括：体育活动和运动伤害的增加、肌腱炎及相关疾病盛行率的上升，以及口服药物技术的进步。

  • 据 Lucintel 预测，由于非类固醇抗发炎药物 (NSAIDs) 的可近性和成本效益，预计在预测期内，NSAIDs 将实现高速成长。
  • 根据应用情况来看，药局预计将迎来高速成长，因为它们提供各种口服药物，例如非类固醇消炎剂和止痛药。
  • 由于肌肉骨骼疾病的高发生率和医疗保健的普及，预计北美在预测期内将出现最高的增长。

肌腱炎口服药物市场的新趋势

治疗腱鞘炎的口服药物市场正经历几个重要的趋势，反映出治疗方式正朝着更有效、以患者为中心的方向转变。

  • 转向生物製药：生物製药正逐渐成为治疗方法慢性肌腱炎的重要手段。这些药物，例如TNF抑制剂，针对潜在的发炎过程，与非类固醇消炎剂（NSAIDs）和皮质类固醇相比，可能具有更长期的疗效和更少的副作用。
  • 个人化医疗：基于基因和分子因素制定的个人化治疗方案正日益普及。透过分析患者独特的发炎标记和遗传易感性，医生可以选择最合适的药物，以改善疗效并减少副作用。
  • 联合治疗：将口服类固醇和非类固醇消炎剂与其他类别的药物（包括生物製药和免疫调节剂）合併使用，正逐渐成为治疗难治性和慢性腱鞘炎的常用方法。这一趋势正促成更个人化和有效的治疗方法。
  • 非处方药选择增加：用于治疗肌腱炎的非处方药越来越普及，使患者更容易获得止痛和消炎治疗。这些非处方药通常以非类固醇消炎剂（NSAIDs）为基础，使用方便，但也受到严格监管以防止滥用。
  • 天然草药疗法：人们对天然草药和口服草药疗法作为传统疗法的辅助或替代疗法越来越感兴趣。姜黄、生姜和其他抗发炎草药作为肌腱炎综合治疗方案的一部分，尤其在印度和中国等地越来越受欢迎。

这些趋势正在重塑市场，为患者提供从生物製药到成药的治疗选择，并推动个人化治疗和自然疗法的创新。

腱鞘炎口服药物市场近期趋势

一些关键进展正在推动肌腱炎口服药物市场向前发展，新的治疗方法、配方和方法正在引入临床。

  • 新型生物製药的核准：包括T​​NF抑制剂在内的生物製药治疗方法的核准和应用，彻底改变了慢性腱鞘炎的治疗。与传统皮质类固醇相比，这些药物具有标靶性强、副作用较少的优势。
  • 非类固醇抗发炎药製剂的进展：新型、更安全的口服非类固醇抗发炎药製剂正在研发中，旨在最大限度地减少消化器官系统副作用，同时保持疗效。这些创新对于提高患者依从性和改善肌腱炎的整体治疗效果至关重要。
  • 个人化医疗方法：基因组学和分子医学的发展正在推动肌腱炎个人化治疗策略的发展。透过根据基因和发炎特征客製化口服药物方案，治疗效果日益显着，副作用风险也得以最小化。
  • 更重视非处方药：用于治疗腱鞘炎的非处方药，包括非类固醇消炎剂和口服抗发炎药，正变得越来越普及。这一趋势使患者能够更好地控制病情，同时降低医疗成本。
  • 天然抗发炎疗法的兴起：姜黄素和生姜等天然药物正越来越多地被纳入口服治疗方案。这些替代疗法在控制肌腱炎相关发炎和疼痛方面的有效性正受到越来越多的研究。

这些发展提高了肌腱炎患者治疗方案的可近性、有效性和多样性，以满足其多样化的需求。

目录

第一章执行摘要

第二章 市场概览

  • 背景和分类
  • 供应链

第三章：市场趋势与预测分析

  • 产业驱动因素与挑战
  • PESTLE分析
  • 专利分析
  • 法规环境

第四章 全球口服腱鞘炎药物市场（按类型划分）

  • 概述
  • 吸引力分析：按类型
  • 非类固醇抗发炎药：趋势与预测（2019-2031 年）
  • 肌腱鬆弛剂、血液循环促进剂与止痛剂：趋势与预测（2019-2031 年）

5. 全球口服腱鞘炎药物市场（依应用划分）

  • 概述
  • 吸引力分析：依目的
  • 医院与诊所：趋势与预测（2019-2031 年）
  • 药学：趋势与预测（2019-2031）
  • 网路购物商城：趋势与预测（2019-2031）

第六章 区域分析

  • 概述
  • 全球口服腱鞘炎药物市场（按地区划分）

7. 北美口服肌腱炎药物市场

  • 概述
  • 北美口服腱鞘炎药物市场（按类型划分）
  • 北美口服腱鞘炎药物市场（按应用领域划分）
  • 美国口服腱鞘炎药物市场
  • 墨西哥口腔腱鞘炎药物市场
  • 加拿大口服肌腱炎药物市场

8. 欧洲口服腱鞘炎药物市场

  • 概述
  • 欧洲口服腱鞘炎药物市场（按类型划分）
  • 欧洲口服腱鞘炎药物市场（按应用领域划分）
  • 德国口服腱鞘炎药物市场
  • 法国口腔腱鞘炎药物市场
  • 西班牙口腔腱鞘炎药物市场
  • 义大利口腔腱鞘炎药物市场
  • 英国口腔腱鞘炎市场

9. 亚太地区口服肌腱炎药物市场

  • 概述
  • 亚太地区口服腱鞘炎药物市场（按类型划分）
  • 亚太地区口服腱鞘炎药物市场（按应用划分）
  • 日本肌腱炎口服药物市场
  • 印度口服腱鞘炎药物市场
  • 中国治疗肌腱炎的口服药物市场
  • 韩国口服腱鞘炎药物市场
  • 印尼口服肌腱炎药物市场

10. 世界其他地区（ROW）口服腱鞘炎药物市场

  • 概述
  • ROW 口服腱鞘炎药物市场（按类型划分）
  • ROW 口服腱鞘炎药物市场（按应用划分）
  • 中东口服腱鞘炎药物市场
  • 南美洲口腔腱鞘炎药物市场
  • 非洲口腔腱鞘炎药物市场

第十一章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析
    • 竞争对手之间的竞争
    • 买方议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 新进入者的威胁
  • 市占率分析

第十二章：机会与策略分析

  • 价值链分析
  • 成长机会分析
    • 按类型分類的成长机会
    • 透过申请获得发展机会
  • 全球肌腱炎口服药物市场的新趋势
  • 战略分析
    • 新产品开发
    • 认证和许可
    • 企业合併、协议、合作关係和合资企业

第十三章：价值链中主要企业的概况

  • 竞争分析
  • Sanofi SA
  • Novartis AG
  • GSK
  • Pfizer
  • Teva
  • Sunflower Pharmaceutical
  • Baiyunshan Pharmaceutical
  • Lingrui Pharmaceutical
  • Bayer
  • Yunnan Baiyao

第十四章附录

  • 图表清单
  • 表格列表
  • 分析方法
  • 免责声明
  • 版权
  • 简称和技术单位
  • 关于 Lucintel
  • 询问

The future of the global oral medicine for tenosynovitis market looks promising with opportunities in the hospital clinic, pharmacy, and online shopping mall markets. The global oral medicine for tenosynovitis market is expected to grow with a CAGR of 3.5% from 2025 to 2031. The major drivers for this market are the rise in physical activity and sports injuries, the rising prevalence of tenosynovitis and related disorders, and the advancements in oral medications.

  • Lucintel forecasts that, within the type category, NSAIDs is expected to witness higher growth over the forecast period due to easily accessible for patients and cost-effective.
  • Within the application category, pharmacy is expected to witness the higher growth due to pharmacies offer a wide range of oral medications, including NSAIDs, analgesics.
  • In terms of region, North America is expected to witness the highest growth over the forecast period due to high prevalence of musculoskeletal disorders, advanced healthcare access.

Emerging Trends in the Oral Medicine for Tenosynovitis Market

The oral medicine for tenosynovitis market is witnessing several key trends, reflecting shifts toward more effective and patient-centered approaches to treatment.

  • Shift to Biologic Therapies: Biologic oral therapies are emerging as an important treatment for chronic tenosynovitis. These medications, such as TNF inhibitors, offer targeted action against the underlying inflammatory processes, providing better long-term relief and fewer side effects compared to traditional NSAIDs and corticosteroids.
  • Personalized Medicine: Tailored treatment plans based on genetic and molecular factors are gaining traction. By analyzing a patient's specific inflammatory markers or genetic predispositions, doctors can select the most appropriate oral medications, improving outcomes and reducing side effects.
  • Combination Therapies: Combining oral corticosteroids or NSAIDs with other classes of drugs, including biologics or immune modulators, is becoming a common approach for managing resistant or chronic cases of tenosynovitis. This trend is leading to more customized and effective treatment regimens.
  • Growth in Over-the-Counter Options: Over-the-counter (OTC) oral medications for tenosynovitis are becoming more widely available, providing patients with easier access to pain relief and anti-inflammatory treatments. These OTC options are typically based on NSAIDs and offer convenience, although they are being closely regulated to prevent misuse.
  • Natural and Herbal Treatments: There is increasing interest in natural and herbal oral medicines as adjuncts or alternatives to conventional treatments. Turmeric, ginger, and other anti-inflammatory herbs are gaining popularity as part of integrated care for tenosynovitis, particularly in regions like India and China.

These trends are reshaping the market by offering patients more treatment options, from biologics to OTC medications, and driving innovation in personalized and natural therapies.

Recent Developments in the Oral Medicine for Tenosynovitis Market

Several key developments are advancing the oral medicine for tenosynovitis market, with new therapies, formulations, and approaches making their way into clinical practice.

  • Approval of New Biologic Agents: The approval and integration of biologic oral medications, including TNF inhibitors, into treatment regimens have marked a significant shift in the management of chronic tenosynovitis. These therapies offer targeted treatment options with fewer side effects compared to traditional corticosteroids.
  • Advancements in NSAID Formulations: New, safer oral NSAID formulations are being developed to minimize gastrointestinal side effects while maintaining efficacy. These innovations are critical in improving patient compliance and overall treatment outcomes for tenosynovitis.
  • Personalized Medicine Approaches: Advances in genomics and molecular medicine have facilitated the development of personalized treatment strategies for tenosynovitis. By tailoring oral drug regimens based on genetic or inflammatory profiles, treatments are becoming more effective and minimizing the risk of adverse effects.
  • Increased Focus on OTC Medications: The availability of over-the-counter medications for tenosynovitis, such as topical NSAIDs and oral anti-inflammatory drugs, is growing. This trend is giving patients more autonomy in managing their condition while reducing healthcare costs.
  • Emergence of Natural Anti-inflammatory Therapies: The integration of natural remedies like curcumin and ginger into oral treatment options is on the rise. These alternatives are increasingly being researched for their efficacy in managing inflammation and pain associated with tenosynovitis.

These developments are improving the availability, efficacy, and variety of treatment options, helping to meet the diverse needs of patients with tenosynovitis.

Strategic Growth Opportunities in the Oral Medicine for Tenosynovitis Market

The oral medicine for tenosynovitis market presents several strategic growth opportunities, particularly in novel treatments and market expansion.

  • Expansion in Emerging Markets: The rising prevalence of musculoskeletal disorders in emerging markets, particularly in regions like India and China, presents a significant opportunity for oral medicines. As healthcare access improves, the demand for effective and affordable treatments is expected to grow.
  • Development of Combination Therapies: The market for combination oral therapies, such as NSAIDs combined with biologics or immune-modulating drugs, is a promising growth area. These treatments offer enhanced effectiveness for patients with resistant or chronic tenosynovitis.
  • Focus on Precision Medicine: There is an increasing opportunity for growth in the precision medicine segment, where treatment is tailored to the individual's genetic profile. This personalized approach is expected to drive more targeted and effective treatments for tenosynovitis.
  • Natural and Alternative Therapies: The growing demand for natural and herbal treatments presents a unique growth opportunity. Manufacturers can explore the development of oral medicines based on proven anti-inflammatory herbs, tapping into consumer preferences for natural solutions.
  • Enhanced Over-the-Counter Offerings: The growing acceptance of over-the-counter oral medicines for musculoskeletal conditions offers a promising opportunity for market growth. Manufacturers can capitalize on this demand by providing safe and effective OTC options for managing tenosynovitis.

These opportunities are expanding the market by offering a variety of treatment options that cater to diverse patient preferences and needs, from biologics to natural therapies.

Oral Medicine for Tenosynovitis Market Driver and Challenges

The oral medicine for tenosynovitis market is influenced by a variety of technological, economic, and regulatory factors, which shape both growth and challenges.

The factors responsible for driving the Oral Medicine for Tenosynovitis market include:

1. Rising Incidence of Musculoskeletal Disorders: The increasing prevalence of conditions like tenosynovitis, especially in aging populations and those with repetitive strain injuries, is a key driver for the demand for oral medicines.

2. Advancements in Drug Formulations: The development of safer, more effective oral formulations of NSAIDs, corticosteroids, and biologics is driving growth in the market, improving patient compliance and outcomes.

3. Demand for Personalized Treatments: The shift toward personalized medicine is enabling more effective and targeted therapies, enhancing treatment outcomes for patients with tenosynovitis and contributing to market growth.

4. Increased Access to Healthcare: Improved access to healthcare, particularly in emerging markets, is fueling demand for oral medications, as patients seek effective and affordable treatments for musculoskeletal conditions.

5. Cost-Effectiveness of Oral Treatments: Oral medications are often more cost-effective compared to injectable or surgical treatments, making them a preferred choice for patients, especially in low-to-middle-income countries.

Challenges in the Oral Medicine for Tenosynovitis market are:

1. Risk of Side Effects: The potential for side effects, such as gastrointestinal issues from NSAIDs and long-term complications from corticosteroids, remains a significant challenge in the market.

2. Regulatory Hurdles: Stricter regulations and lengthy approval processes for new oral medicines can delay market entry and limit the pace of innovation, hindering growth.

3. Patient Compliance: While oral medications are generally more convenient, patient adherence to long-term treatment regimens can still be a challenge, especially for chronic cases of tenosynovitis.

These drivers and challenges influence the overall growth trajectory of the oral medicine market, highlighting the need for innovative, patient-centered treatments while addressing concerns related to side effects and regulatory approvals.

List of Oral Medicine for Tenosynovitis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies oral medicine for tenosynovitis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the oral medicine for tenosynovitis companies profiled in this report include-

  • Sanofi S.A.
  • Novartis AG
  • GSK
  • Pfizer
  • Teva
  • Sunflower Pharmaceutical
  • Baiyunshan Pharmaceutical
  • Lingrui Pharmaceutical
  • Bayer
  • Yunnan Baiyao

Oral Medicine for Tenosynovitis Market by Segment

The study includes a forecast for the global oral medicine for tenosynovitis market by type, application, and region.

Oral Medicine for Tenosynovitis Market by Type [Value from 2019 to 2031]:

  • NSAIDs
  • Relaxing Tendons, Activating Blood Circulation And Analgesic

Oral Medicine for Tenosynovitis Market by Application [Value from 2019 to 2031]:

  • Hospital Clinic
  • Pharmacy
  • Online Shopping Mall

Oral Medicine for Tenosynovitis Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Oral Medicine for Tenosynovitis Market

The oral medicine for tenosynovitis market, a condition involving inflammation of the tendons and their surrounding sheaths, has seen several developments worldwide. These advancements reflect an increased understanding of the disease, improved oral treatment options, and growing demand for effective therapies to manage inflammation and pain. The global market for oral medications used in treating tenosynovitis is driven by factors such as better drug formulations, patient-centered treatments, and the rising prevalence of musculoskeletal disorders. Key regions such as the United States, China, Germany, India, and Japan are contributing to these advancements with innovative therapies and improving healthcare access.

  • United States: In the U.S., there has been significant development in the use of oral corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) for the management of tenosynovitis. Additionally, biologic therapies are gaining attention for patients with chronic or resistant cases. Recent research focuses on the effectiveness of combination therapies and long-term treatment strategies, leading to better clinical outcomes. The U.S. also leads in the approval of new oral medications targeting inflammation and pain, driving market growth.
  • China: The oral medicine for tenosynovitis market in China is experiencing growth, particularly with the increasing awareness of musculoskeletal conditions. China is expanding its use of oral NSAIDs and corticosteroids, though there is a growing push for alternative treatments like natural anti-inflammatory agents. Due to the rising aging population and prevalence of repetitive stress injuries, the demand for effective oral treatments is expected to continue to increase, leading to innovations in both traditional and modern therapeutic approaches.
  • Germany: Germany has a robust healthcare system that emphasizes both conventional treatments and innovative therapies. The market for oral medicine targeting tenosynovitis is advancing with the growing use of biologics and disease-modifying drugs. Germany is also a key player in research focused on oral formulations of corticosteroids and NSAIDs that offer targeted relief. The regulatory environment in Germany supports the development of novel treatments, creating a favorable market for new oral drugs.
  • India: In India, tenosynovitis treatment is increasingly being managed with oral NSAIDs, corticosteroids, and other medications that address inflammation. The market is expanding due to a rising incidence of musculoskeletal disorders, particularly in the working population. Additionally, cost-effective oral therapies are gaining popularity in India, with a significant focus on improving access to medications. There is also interest in exploring traditional herbal medicines as adjuncts to conventional treatments.
  • Japan: Japan is focusing on precision medicine in the treatment of tenosynovitis, with the growing use of oral biologic agents and advanced NSAIDs. The country has a high demand for effective oral treatments, especially among older populations, who are more prone to tendonitis and related conditions. Japan's healthcare system supports the development and use of new oral therapies that are both effective and safe, ensuring rapid adoption of novel treatments in clinical settings.

Features of the Global Oral Medicine for Tenosynovitis Market

  • Market Size Estimates: Oral medicine for tenosynovitis market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Oral medicine for tenosynovitis market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Oral medicine for tenosynovitis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the oral medicine for tenosynovitis market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the oral medicine for tenosynovitis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the oral medicine for tenosynovitis market by type (NSAIDs and relaxing tendons, activating blood circulation and analgesic), application (hospital clinic, pharmacy, and online shopping mall), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Oral Medicine for Tenosynovitis Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 NSAIDs: Trends and Forecast (2019-2031)
  • 4.4 Relaxing Tendons, Activating Blood Circulation and Analgesic: Trends and Forecast (2019-2031)

5. Global Oral Medicine for Tenosynovitis Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Hospital Clinic: Trends and Forecast (2019-2031)
  • 5.4 Pharmacy: Trends and Forecast (2019-2031)
  • 5.5 Online Shopping Mall: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Oral Medicine for Tenosynovitis Market by Region

7. North American Oral Medicine for Tenosynovitis Market

  • 7.1 Overview
  • 7.2 North American Oral Medicine for Tenosynovitis Market by type
  • 7.3 North American Oral Medicine for Tenosynovitis Market by application
  • 7.4 United States Oral Medicine for Tenosynovitis Market
  • 7.5 Mexican Oral Medicine for Tenosynovitis Market
  • 7.6 Canadian Oral Medicine for Tenosynovitis Market

8. European Oral Medicine for Tenosynovitis Market

  • 8.1 Overview
  • 8.2 European Oral Medicine for Tenosynovitis Market by type
  • 8.3 European Oral Medicine for Tenosynovitis Market by application
  • 8.4 German Oral Medicine for Tenosynovitis Market
  • 8.5 French Oral Medicine for Tenosynovitis Market
  • 8.6 Spanish Oral Medicine for Tenosynovitis Market
  • 8.7 Italian Oral Medicine for Tenosynovitis Market
  • 8.8 United Kingdom Oral Medicine for Tenosynovitis Market

9. APAC Oral Medicine for Tenosynovitis Market

  • 9.1 Overview
  • 9.2 APAC Oral Medicine for Tenosynovitis Market by type
  • 9.3 APAC Oral Medicine for Tenosynovitis Market by application
  • 9.4 Japanese Oral Medicine for Tenosynovitis Market
  • 9.5 Indian Oral Medicine for Tenosynovitis Market
  • 9.6 Chinese Oral Medicine for Tenosynovitis Market
  • 9.7 South Korean Oral Medicine for Tenosynovitis Market
  • 9.8 Indonesian Oral Medicine for Tenosynovitis Market

10. ROW Oral Medicine for Tenosynovitis Market

  • 10.1 Overview
  • 10.2 ROW Oral Medicine for Tenosynovitis Market by type
  • 10.3 ROW Oral Medicine for Tenosynovitis Market by application
  • 10.4 Middle Eastern Oral Medicine for Tenosynovitis Market
  • 10.5 South American Oral Medicine for Tenosynovitis Market
  • 10.6 African Oral Medicine for Tenosynovitis Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Oral Medicine for Tenosynovitis Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Sanofi S.A.
    • Company Overview
    • Oral Medicine for Tenosynovitis Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Novartis AG
    • Company Overview
    • Oral Medicine for Tenosynovitis Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 GSK
    • Company Overview
    • Oral Medicine for Tenosynovitis Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Pfizer
    • Company Overview
    • Oral Medicine for Tenosynovitis Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Teva
    • Company Overview
    • Oral Medicine for Tenosynovitis Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Sunflower Pharmaceutical
    • Company Overview
    • Oral Medicine for Tenosynovitis Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Baiyunshan Pharmaceutical
    • Company Overview
    • Oral Medicine for Tenosynovitis Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.9 Lingrui Pharmaceutical
    • Company Overview
    • Oral Medicine for Tenosynovitis Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.10 Bayer
    • Company Overview
    • Oral Medicine for Tenosynovitis Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.11 Yunnan Baiyao
    • Company Overview
    • Oral Medicine for Tenosynovitis Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Oral Medicine for Tenosynovitis Market
  • Figure 2.1: Usage of Oral Medicine for Tenosynovitis Market
  • Figure 2.2: Classification of the Global Oral Medicine for Tenosynovitis Market
  • Figure 2.3: Supply Chain of the Global Oral Medicine for Tenosynovitis Market
  • Figure 3.1: Driver and Challenges of the Oral Medicine for Tenosynovitis Market
  • Figure 3.2: PESTLE Analysis
  • Figure 3.3: Patent Analysis
  • Figure 3.4: Regulatory Environment
  • Figure 4.1: Global Oral Medicine for Tenosynovitis Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Oral Medicine for Tenosynovitis Market ($B) by Type
  • Figure 4.3: Forecast for the Global Oral Medicine for Tenosynovitis Market ($B) by Type
  • Figure 4.4: Trends and Forecast for NSAIDs in the Global Oral Medicine for Tenosynovitis Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Relaxing Tendons, Activating Blood Circulation and Analgesic in the Global Oral Medicine for Tenosynovitis Market (2019-2031)
  • Figure 5.1: Global Oral Medicine for Tenosynovitis Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Oral Medicine for Tenosynovitis Market ($B) by Application
  • Figure 5.3: Forecast for the Global Oral Medicine for Tenosynovitis Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Hospital Clinic in the Global Oral Medicine for Tenosynovitis Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Pharmacy in the Global Oral Medicine for Tenosynovitis Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Online Shopping Mall in the Global Oral Medicine for Tenosynovitis Market (2019-2031)
  • Figure 6.1: Trends of the Global Oral Medicine for Tenosynovitis Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Oral Medicine for Tenosynovitis Market ($B) by Region (2025-2031)
  • Figure 7.1: North American Oral Medicine for Tenosynovitis Market by type in 2019, 2024, and 2031
  • Figure 7.2: Trends of the North American Oral Medicine for Tenosynovitis Market ($B) by type (2019-2024)
  • Figure 7.3: Forecast for the North American Oral Medicine for Tenosynovitis Market ($B) by type (2025-2031)
  • Figure 7.4: North American Oral Medicine for Tenosynovitis Market by application in 2019, 2024, and 2031
  • Figure 7.5: Trends of the North American Oral Medicine for Tenosynovitis Market ($B) by application (2019-2024)
  • Figure 7.6: Forecast for the North American Oral Medicine for Tenosynovitis Market ($B) by application (2025-2031)
  • Figure 7.7: Trends and Forecast for the United States Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 7.8: Trends and Forecast for the Mexican Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Canadian Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 8.1: European Oral Medicine for Tenosynovitis Market by type in 2019, 2024, and 2031
  • Figure 8.2: Trends of the European Oral Medicine for Tenosynovitis Market ($B) by type (2019-2024)
  • Figure 8.3: Forecast for the European Oral Medicine for Tenosynovitis Market ($B) by type (2025-2031)
  • Figure 8.4: European Oral Medicine for Tenosynovitis Market by application in 2019, 2024, and 2031
  • Figure 8.5: Trends of the European Oral Medicine for Tenosynovitis Market ($B) by application (2019-2024)
  • Figure 8.6: Forecast for the European Oral Medicine for Tenosynovitis Market ($B) by application (2025-2031)
  • Figure 8.7: Trends and Forecast for the German Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 8.8: Trends and Forecast for the French Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the Spanish Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Italian Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the United Kingdom Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 9.1: APAC Oral Medicine for Tenosynovitis Market by type in 2019, 2024, and 2031
  • Figure 9.2: Trends of the APAC Oral Medicine for Tenosynovitis Market ($B) by type (2019-2024)
  • Figure 9.3: Forecast for the APAC Oral Medicine for Tenosynovitis Market ($B) by type (2025-2031)
  • Figure 9.4: APAC Oral Medicine for Tenosynovitis Market by application in 2019, 2024, and 2031
  • Figure 9.5: Trends of the APAC Oral Medicine for Tenosynovitis Market ($B) by application (2019-2024)
  • Figure 9.6: Forecast for the APAC Oral Medicine for Tenosynovitis Market ($B) by application (2025-2031)
  • Figure 9.7: Trends and Forecast for the Japanese Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 9.8: Trends and Forecast for the Indian Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Chinese Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the South Korean Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the Indonesian Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 10.1: ROW Oral Medicine for Tenosynovitis Market by type in 2019, 2024, and 2031
  • Figure 10.2: Trends of the ROW Oral Medicine for Tenosynovitis Market ($B) by type (2019-2024)
  • Figure 10.3: Forecast for the ROW Oral Medicine for Tenosynovitis Market ($B) by type (2025-2031)
  • Figure 10.4: ROW Oral Medicine for Tenosynovitis Market by application in 2019, 2024, and 2031
  • Figure 10.5: Trends of the ROW Oral Medicine for Tenosynovitis Market ($B) by application (2019-2024)
  • Figure 10.6: Forecast for the ROW Oral Medicine for Tenosynovitis Market ($B) by application (2025-2031)
  • Figure 10.7: Trends and Forecast for the Middle Eastern Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 10.8: Trends and Forecast for the South American Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the African Oral Medicine for Tenosynovitis Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Oral Medicine for Tenosynovitis Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Oral Medicine for Tenosynovitis Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Oral Medicine for Tenosynovitis Market by Type
  • Figure 12.2: Growth Opportunities for the Global Oral Medicine for Tenosynovitis Market by Application
  • Figure 12.3: Growth Opportunities for the Global Oral Medicine for Tenosynovitis Market by Region
  • Figure 12.4: Emerging Trends in the Global Oral Medicine for Tenosynovitis Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Oral Medicine for Tenosynovitis Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Oral Medicine for Tenosynovitis Market by Region
  • Table 1.3: Global Oral Medicine for Tenosynovitis Market Parameters and Attributes
  • Table 3.1: Trends of the Global Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 3.2: Forecast for the Global Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Oral Medicine for Tenosynovitis Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 4.4: Trends of NSAIDs in the Global Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 4.5: Forecast for NSAIDs in the Global Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 4.6: Trends of Relaxing Tendons, Activating Blood Circulation and Analgesic in the Global Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 4.7: Forecast for Relaxing Tendons, Activating Blood Circulation and Analgesic in the Global Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Oral Medicine for Tenosynovitis Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 5.4: Trends of Hospital Clinic in the Global Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 5.5: Forecast for Hospital Clinic in the Global Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 5.6: Trends of Pharmacy in the Global Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 5.7: Forecast for Pharmacy in the Global Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 5.8: Trends of Online Shopping Mall in the Global Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 5.9: Forecast for Online Shopping Mall in the Global Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 7.1: Trends of the North American Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 7.2: Forecast for the North American Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various type in the North American Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various type in the North American Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various application in the North American Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various application in the North American Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 8.1: Trends of the European Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 8.2: Forecast for the European Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various type in the European Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various type in the European Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various application in the European Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various application in the European Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 9.1: Trends of the APAC Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 9.2: Forecast for the APAC Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various type in the APAC Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various type in the APAC Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various application in the APAC Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various application in the APAC Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 10.1: Trends of the ROW Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 10.2: Forecast for the ROW Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various type in the ROW Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various type in the ROW Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various application in the ROW Oral Medicine for Tenosynovitis Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various application in the ROW Oral Medicine for Tenosynovitis Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Oral Medicine for Tenosynovitis Market (2019-2031)
  • Table 11.1: Product Mapping of Oral Medicine for Tenosynovitis Suppliers Based on Segments
  • Table 11.2: Operational Integration of Oral Medicine for Tenosynovitis Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Oral Medicine for Tenosynovitis Revenue
  • Table 12.1: New Product Launches by Major Oral Medicine for Tenosynovitis Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Oral Medicine for Tenosynovitis Market